achieve life sciences (Seite 33)
eröffnet am 24.06.18 15:20:22 von
neuester Beitrag 10.01.23 19:02:02 von
neuester Beitrag 10.01.23 19:02:02 von
Beiträge: 1.058
ID: 1.283.149
ID: 1.283.149
Aufrufe heute: 0
Gesamt: 95.849
Gesamt: 95.849
Aktive User: 0
ISIN: US0044685008 · WKN: A2QAR3 · Symbol: ACHV
4,5350
USD
+2,83 %
+0,1250 USD
Letzter Kurs 19:20:59 Nasdaq
Neuigkeiten
11.04.24 · globenewswire  |
28.03.24 · globenewswire |
20.03.24 · globenewswire |
14.03.24 · globenewswire |
06.03.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,5800 | +922,86 | |
| 0,8800 | +95,56 | |
| 0,5777 | +25,59 | |
| 384,00 | +20,00 | |
| 5,9050 | +17,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,5000 | -24,62 | |
| 14,510 | -32,32 | |
| 71,33 | -33,92 | |
| 3,6400 | -38,62 | |
| 0,7000 | -61,85 |
Beitrag zu dieser Diskussion schreiben
Feedback!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: unnötige Provokation, bleiben Sie bitte sachlich, persönliche Angriffe bitte unterlassen!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: unnötige Provokation, bleiben Sie bitte sachlich, persönliche Angriffe bitte unterlassen
Antwort auf Beitrag Nr.: 62.360.402 von LetzCrash am 13.01.20 17:17:54Nachtrag:
Wäre SONST schade drum!
Das Wort muss schon mit 😉
Wäre SONST schade drum!
Das Wort muss schon mit 😉
Antwort auf Beitrag Nr.: 62.359.694 von MichaNRW am 13.01.20 16:31:36Hi Micha
Dann hoffen wir mal, dass die "leichte" Konsolidierung keine bleibende ist.
Bisher scheint der Anstieg letzte fast komplett wieder aufgegessen.
Jetzt zwar keine Panik, aber schon ein krasser Sprung nach unten. Momentan zumindest. Kann ja aber auch sein, dass es sich bis BS wieder fängt. Wäre schade drum
Gruß
Dann hoffen wir mal, dass die "leichte" Konsolidierung keine bleibende ist.
Bisher scheint der Anstieg letzte fast komplett wieder aufgegessen.
Jetzt zwar keine Panik, aber schon ein krasser Sprung nach unten. Momentan zumindest. Kann ja aber auch sein, dass es sich bis BS wieder fängt. Wäre schade drum
Gruß
Hallo zuammen,
leichte Konolodierung nach dem Run vom Freitag, der Kurs scheint stabilisiert. Das ganze gleicht sehr dem letzten Montag ,auch dort ging es ein wenig in die Knie... Der nächste Run kommt bestimmt. Der Wert swingt seit Tage ordentlich hin und her, wobei alte Tiefs nicht mehr erreicht werden aber immer höhere Kurse... Kurstechnisch sehr gesund da nicht überhitzt. ... Die Amis sind guter Dinge siehe Stockwits...
Grüße
Micha
leichte Konolodierung nach dem Run vom Freitag, der Kurs scheint stabilisiert. Das ganze gleicht sehr dem letzten Montag ,auch dort ging es ein wenig in die Knie... Der nächste Run kommt bestimmt. Der Wert swingt seit Tage ordentlich hin und her, wobei alte Tiefs nicht mehr erreicht werden aber immer höhere Kurse... Kurstechnisch sehr gesund da nicht überhitzt. ... Die Amis sind guter Dinge siehe Stockwits...
Grüße
Micha
Trading Spotlight
Hallo zusammen
Bleibt wohl abzuwarten, wo die Aktie heute stehen bleibt.
Der gute Start hier ist wohl dankend angenommen und auch gleich umgesetzt worden in den USA.
Ob diese news jetzt der reisser war, welche ab jetzt den Wert stetig gen Norden treibt? Hab mich in den amerikanischen Foren noch nicht umgeschaut. Weiß jemand was, ob da noch Hochstimmung herrscht?
Gruß
Bleibt wohl abzuwarten, wo die Aktie heute stehen bleibt.
Der gute Start hier ist wohl dankend angenommen und auch gleich umgesetzt worden in den USA.
Ob diese news jetzt der reisser war, welche ab jetzt den Wert stetig gen Norden treibt? Hab mich in den amerikanischen Foren noch nicht umgeschaut. Weiß jemand was, ob da noch Hochstimmung herrscht?
Gruß
Mit positiven News in den naechsten Monaten ist eine MK von max. $50Mio in Reichweite
entspricht einen Kurs von $1.92. Hoehere kursbewegungen (Kursspitzen $3.0 - 3.5)
sind nicht auseschlossen ACHV ist bekannt als Zocker Aktie.
Vorsicht ab 3. Quartal 2020 dann brauchen sie wieder neues Kapital auch wenn die
III Phase erfolgreich abeschlossen wurde.
entspricht einen Kurs von $1.92. Hoehere kursbewegungen (Kursspitzen $3.0 - 3.5)
sind nicht auseschlossen ACHV ist bekannt als Zocker Aktie.
Vorsicht ab 3. Quartal 2020 dann brauchen sie wieder neues Kapital auch wenn die
III Phase erfolgreich abeschlossen wurde.
Antwort auf Beitrag Nr.: 62.357.870 von flexfon am 13.01.20 13:51:36es sind 25 mio shares, wobei mit den warrants noch 10 mio dazu kommen können. die mk liegt bei 14 mio euro. das ek liegt bei 8mio dollar, also 7 mio euro. man zahlt also aktuell das doppelte ek. ich finde, da ist schon viel phantasie mit eingepreist. andererseits ist hier wohl alles im euphoriemodus, von daher gehe ich von steigenden kursen aus. nur den ausstieg nicht verpassen. und ich würde auch eher in usa kaufen, da ist der markt liquider.
The study, "A General Mechanism for Signal Propagation in the Nicotinic Acetylcholine Receptor Family," was led by scientists from the University of Bristol and recently published in the Journal of the American Chemical Society. It aimed to evaluate how receptors in the brain respond to nicotine. Researchers utilized new computational simulation methods to conduct 450 individual assessments of the biochemistry associated with the binding of nicotine to a subtype of nicotinic acetylcholine receptors, a key mechanism believed to be responsible for the highly-addictive nature of nicotine.
Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure. The speed of results represents a breakthrough in computational chemistry and is transformational from a research perspective.
"To understand why nicotine is so addictive, and to develop molecules to help people quit smoking, we need to understand how nicotine affects the nervous system," commented Professor Adrian Mulholland from Bristol's Centre for Computational Chemistry and co-author of the study. "By harnessing the power of cloud computing, we can quickly observe how nicotine exerts its effects at the molecular level. This information can inform future drug development of new treatments for companies like Achieve."
Achieve Life Sciences has partnered with the University of Bristol to formulate molecules and potential treatments to combat addiction and neurological disorders based on their lead smoking cessation compound in development, cytisinicline. Building on this research and previously conducted studies, cloud-based computer simulations can now be utilized to evaluate the effectiveness of potential new treatments more efficiently and help to accelerate the pace of discovery.
About Achieve & Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide.1 It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking.2 Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Jason Wong
Computations that would otherwise have taken months to complete were achieved in five days using Oracle's high-performance cloud infrastructure. The speed of results represents a breakthrough in computational chemistry and is transformational from a research perspective.
"To understand why nicotine is so addictive, and to develop molecules to help people quit smoking, we need to understand how nicotine affects the nervous system," commented Professor Adrian Mulholland from Bristol's Centre for Computational Chemistry and co-author of the study. "By harnessing the power of cloud computing, we can quickly observe how nicotine exerts its effects at the molecular level. This information can inform future drug development of new treatments for companies like Achieve."
Achieve Life Sciences has partnered with the University of Bristol to formulate molecules and potential treatments to combat addiction and neurological disorders based on their lead smoking cessation compound in development, cytisinicline. Building on this research and previously conducted studies, cloud-based computer simulations can now be utilized to evaluate the effectiveness of potential new treatments more efficiently and help to accelerate the pace of discovery.
About Achieve & Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for more than eight million deaths annually worldwide.1 It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking.2 Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.
As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the timing and nature of cytisinicline clinical development activities, the potential market size for cytisinicline, the potential benefits of cytisinicline, the ability to discover and develop new uses for cytisinicline and the development and effectiveness of new treatments. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Achieve Contact
Jason Wong
Es sind 20,7 Mio Aktien draußen MK 12 Mio
News sind auch raus auf der Homepage
News sind auch raus auf der Homepage
Durchsuchen
